ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Astellas signs bispecific pact with Pandion

by Ryan Cross
November 2, 2019 | APPEARED IN VOLUME 97, ISSUE 43

Astellas Pharma has signed a research pact with Pandion Therapeutics, a start-up in Cambridge, Massachusetts, developing bispecific antibodies for pancreatic autoimmune diseases, particularly type 1 diabetes. Pandion is developing drugs that target specific tissues and simultaneously turn down aberrant immune cell responses that cause autoimmune disease. Astellas will pay Pandion up to $45 million up front and potentially more than $750 million in milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment